Your institution may have access to this item. Find your institution then sign in to continue.
Title
NEW COMBINATION.
Abstract
The article focuses on the FDA's accelerated approval of Akeega, a novel combination tablet for the treatment of BRCA-mutated metastatic prostate cancer, highlighting its significant impact on radiographic progression-free survival in patients with these mutations. It includes the drug's dual-action mechanism, the positive results from the MAGNITUDE study, and the notable adverse reactions observed in patients receiving the treatment.